tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Veeva Systems: Broad Biopharma Demand, Emerging AI Traction, and Durable Moat Support Long‑Term Growth and Justify Buy Rating
PremiumRatingsVeeva Systems: Broad Biopharma Demand, Emerging AI Traction, and Durable Moat Support Long‑Term Growth and Justify Buy Rating
17d ago
Veeva price target lowered to $262 from $275 at Truist
Premium
The Fly
Veeva price target lowered to $262 from $275 at Truist
17d ago
Veeva price target lowered to $275 from $330 at RBC Capital
Premium
The Fly
Veeva price target lowered to $275 from $330 at RBC Capital
17d ago
Veeva price target lowered to $285 from $355 at Piper Sandler
PremiumThe FlyVeeva price target lowered to $285 from $355 at Piper Sandler
17d ago
Veeva price target raised to $215 from $205 at Morgan Stanley
Premium
The Fly
Veeva price target raised to $215 from $205 at Morgan Stanley
17d ago
Veeva price target raised to $220 from $200 at UBS
Premium
The Fly
Veeva price target raised to $220 from $200 at UBS
17d ago
Veeva price target lowered to $317 from $333 at Wells Fargo
PremiumThe FlyVeeva price target lowered to $317 from $333 at Wells Fargo
17d ago
Closing Bell Movers: Veeva up 13%, Broadcom up 5% on earnings beat
Premium
The Fly
Closing Bell Movers: Veeva up 13%, Broadcom up 5% on earnings beat
18d ago
Veeva reports Q4 non-GAAP EPS $2.06, consensus $1.94
Premium
The Fly
Veeva reports Q4 non-GAAP EPS $2.06, consensus $1.94
18d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100